EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter phase II study of sequential hormonotherapy with Anastrozl/Exemestane in metastatic breast disease Preliminary data of goim 2107 Study



Multicenter phase II study of sequential hormonotherapy with Anastrozl/Exemestane in metastatic breast disease Preliminary data of goim 2107 Study



EJC Supplements 1(5): S139, September




(PDF 0-2 workdays service: $29.90)

Accession: 035349870

Download citation: RISBibTeXText



Related references

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology 15(2): 211-217, 2004

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. Journal of Clinical Oncology 17(11): 3418-3425, 1999

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology 14(9): 1391-1398, 2003

Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Research and Treatment 116(3): 501-508, 2008

Exemestane (Exe) as primary treatment in hormonosensible early breast cancer of the elderly: Preliminary results of a phase II multicenter open Italian study. Journal of Clinical Oncology 24(18_suppl): 10689-10689, 2016

Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology 17 Suppl 7(): Vii73-7, 2006

Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clinical Breast Cancer 6 Suppl 2: S41-S44, 2006

Treatment of advanced metastatic breast cancer with exemestane, a multicenter randomized controlled study of 195 cases. Zhonghua Yi Xue Za Zhi 83(3): 188-190, 2003

Metastatic breast carcinoma: sequential hormonotherapy with tamoxifen and medroxy-progesterone acetate. preliminary results. Bulletin du Cancer 69(2): 170-171, 1982

Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. Future Oncology 10(5): 725-733, 2014

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. European Journal of Cancer 33(11): 1767-1773, 1998

Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Anti-Cancer Drugs 8(10): 943-948, 1998

Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: A phase II study of the Southern Italy Oncology Group (GOIM). Anti Cancer Drugs 8(10): 943-948, 1997

Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clinical Breast Cancer 1 Suppl 1: S15-S18, 2002

Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study. Clinical Breast Cancer 10(4): 313-317, 2010